1. Home >
  2. M&A >
  3. Divestiture >
  4. United Kingdom >
  5. Rayner Acquires OMIDRIA

M&A Deal Summary

Rayner Acquires OMIDRIA

On December 2, 2021, Rayner acquired life science company OMIDRIA from Omeros

Acquisition Highlights
  • This is Rayner’s 1st transaction in the Life Science sector.
  • This is Rayner’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-12-02
Target OMIDRIA
Sector Life Science
Buyer(s) Rayner
Sellers(s) Omeros
Deal Type Divestiture

Target

OMIDRIA

United Kingdom
OMIDRIA is a phenylephrine and ketorolac intraocular solution 1% / 0.3% is the first and only FDA-approved product of its kind and is marketed in the U.S. for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Rayner

Worthing, United Kingdom
Category Company
Founded 1910
Sector Medical Products
DESCRIPTION

Rayner is a developer and manufacturer of ophthalmic implants and pharmaceuticals. It specialises in intra-ocular lenses (IOLs) and related products used in cataract and refractive surgery, the most commonly performed surgical procedure globally, with more than 24 million performed each year. Rayner was established in 1910 and is based in Worthing, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2021 M&A 1 of 1

Seller(S) 1

SELLER

Omeros

Seattle, Washington, United States
Category Company
Founded 1994
Sector Life Science
Employees202
Revenue 169M USD (2024)
DESCRIPTION

Omeros is a clinical-stage bio-pharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. Omeros was founded in 1994 and is based in Seattle, Washington.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2021 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-09-07 Nura

Seattle, Washington, United States

Nura, Inc. is a provider in developing treatments for pain and other central nervous system disorders including schizophrenia and Parkinson's disease.

Buy -
Mergr

Solution for

Product

Company

Legal